Efficacy outcomes:
The primary efficacy outcomes were composite of kidney failure: “a
sustained decrease of at least 40% in the eGFR from baseline over a
period of at least 4 weeks, or death from renal causes. Kidney failure
was defined as end-stage kidney disease or an eGFR of less than 15 ml
per minute per 1.73 m2; end-stage kidney disease was defined as the
initiation of long-term dialysis (for ≥90 days) or kidney
transplantation”, composite of death from cardiovascular causes:
nonfatal myocardial infarction, nonfatal stroke, or hospitalization for
heart failure. Other secondary outcomes were death from any cause,
hospitalization for any cause, the change in the urinary
albumin-to-creatinine ratio from baseline to month 4, and a composite of
kidney failure, a sustained decrease of at least 57% in the eGFR from
baseline (equivalent to a doubling of the serum creatinine level)
maintained for at least 4 weeks, or death from renal causes.